The market for menopause care, previously underserved, is experiencing a resurgence, with projections indicating substantial growth. The annual market for US menopause healthcare could reach almost $40 billion by 2030, an eightfold increase, if all women with moderate to severe symptoms receive adequate treatment. The broader category of midlife women's health is estimated at $360 billion. This growth is fueled by increasing demand for high-quality midlife care, as women become more informed and vocal about their needs.
Key market opportunities exist in biopharmaceuticals, medical technology, and consumer health. While traditional hormone therapy (MHT) is seeing renewed support, non-hormonal medications are expected to be a major growth driver in biopharma sales. Consumer health products, including supplements and test kits, could reach $12 billion by 2030, particularly those that are scientifically proven. Companies like MidiHealth, a telehealth platform focused on midlife women's health, have already achieved a $1 billion valuation.
The economic impact of untreated menopause symptoms is significant. Missed workdays due to these symptoms result in an estimated $1.8 billion in lost wages annually, and this figure rises to $26.6 billion when factoring in additional related healthcare costs. Approximately 20% of menopausal women in the US have either left or considered leaving their jobs due to untreated symptoms, leading to increased demand for menopause-specific work benefits. However, a $19 billion gray market also exists, posing risks to menopausal women seeking solutions.
